LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.08 1.89

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.03

Max

1.09

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+112.26% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-39M 135M
Eelmine avamishind	-0.81
Eelmine sulgemishind	1.08

Uudiste sentiment

By Acuity

42%

58%

128 / 350 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. märts 2026, 18:34 UTC

Tulu

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

19. märts 2026, 17:43 UTC

Suurimad hinnamuutused turgudel

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning: Outdoor Category Continued Growing >2331.HK

19. märts 2026, 23:38 UTC

Tulu

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

19. märts 2026, 23:33 UTC

Market Talk

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

McCormick Has a Market Value of Around $14.8B -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

19. märts 2026, 22:23 UTC

Market Talk

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

19. märts 2026, 22:09 UTC

Market Talk

Uudisväärsed sündmused

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

19. märts 2026, 22:06 UTC

Market Talk

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

19. märts 2026, 22:04 UTC

Tulu

Omandamised, ülevõtmised, äriostud

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

19. märts 2026, 22:03 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

19. märts 2026, 22:03 UTC

Market Talk

Uudisväärsed sündmused

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

19. märts 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

19. märts 2026, 20:57 UTC

Uudisväärsed sündmused

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

19. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

19. märts 2026, 20:19 UTC

Uudisväärsed sündmused

Brent Crude Retreats After Touching $119 -- WSJ

19. märts 2026, 19:49 UTC

Market Talk

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

19. märts 2026, 19:26 UTC

Uudisväärsed sündmused

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

19. märts 2026, 19:10 UTC

Market Talk

Uudisväärsed sündmused

Natural Gas Rises in Volatile Trading -- Market Talk

19. märts 2026, 19:06 UTC

Uudisväärsed sündmused

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

19. märts 2026, 18:08 UTC

Market Talk

Uudisväärsed sündmused

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

112.26% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD 112.26%

Kõrge 2.5 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

128 / 350 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.